Related Experiment Video

Updated: Aug 24, 2025

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

9.6K

[NTRK Gene Fusions and Treatment in NTRK Fusion-Positive Solid Cancers]

Misao Fukuda1, Yoichi Naito

  • 1Dept. of Medical Oncology, National Cancer Center Hospital East.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 25, 2022
PubMed

Insights

Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare in most cancers but drive specific tumor types. Approved NTRK inhibitors offer durable responses, with next-generation drugs aiming to overcome resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Context:

  • Neurotrophic tyrosine receptor kinase (NTRK) gene variants are identified across diverse solid tumors.
  • While generally rare (<1%), NTRK gene fusions show higher prevalence in specific cancers like secretory breast carcinoma and infantile fibrosarcoma.
  • Detection methods include RT-PCR and comprehensive genomic profiling.

Purpose:

  • To review the landscape of NTRK gene variants in solid tumors.
  • To discuss current NTRK inhibitors and their limitations.
  • To highlight the need for next-generation inhibitors.

Summary:

  • NTRK gene fusions, though infrequent overall, are significant drivers in certain rare cancers.
  • Entrectinib and larotrectinib are approved NTRK inhibitors demonstrating efficacy in NTRK fusion-positive solid tumors.
  • Acquired resistance can limit the duration of response to current therapies.

Impact:

  • NTRK inhibitors represent a targeted therapy approach for specific cancer subsets.
  • Understanding NTRK fusion prevalence and resistance mechanisms is crucial for optimizing treatment strategies.
  • Development of next-generation TRK inhibitors holds promise for overcoming acquired resistance and improving patient outcomes.

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
79.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
639
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K